Genentech

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company based in Abingdon, United Kingdom, specializing in innovative cell therapies for cancer treatment, particularly targeting solid tumors. The company utilizes its specific peptide enhanced affinity receptor (SPEAR) T-cell platform to identify and genetically engineer T-cell receptors that enhance the immune response against cancerous cells. Current clinical trials are exploring various therapeutic candidates, including ADP-A2M4 for multiple solid tumor types and ADP-A2AFP for hepatocellular carcinoma. Adaptimmune has formed strategic collaborations with several organizations, including GSK for the development of NY-ESO T-cell therapy and Noile-Immune Biotech Inc. for combining SPEAR T-cells with PRIME technology. Founded in 2008, Adaptimmune is committed to advancing T-cell therapies to improve patient outcomes in oncology and beyond.

Jecure Therapeutics, Inc. is a biotechnology company based in San Diego, California, established in 2015 and operating as a subsidiary of Genentech, Inc. The company specializes in the development of small-molecule therapeutics aimed at treating non-alcoholic steatohepatitis (NASH) and liver fibrosis. Jecure Therapeutics focuses on blocking inflammasome activation and disrupting the sterile inflammation loop associated with hepatocellular injury and cell death. The company employs innovative drug discovery programs, utilizing siRNA-based murine fibrosis models for target identification and validation, as well as unique in vivo screening models to capture key disease features. This approach enables effective identification of drug candidates that can intervene throughout the progression of these serious inflammatory diseases.

Seragon Pharmaceuticals, Inc., headquartered in Irvine, California, is a research-based biopharmaceutical company dedicated to improving human and animal health through innovative science. Seragon Pharmaceuticals is committed to applying cutting-edge scientific and technological advancements to the fields of metabolism, gene therapy and bioinformatics. From the research end to consumer products and clinical applications, Seragon strives to bring people access to the most significant breakthroughs in medicine. For more information, please visit www.seragon.com

Rock Health is a venture capital firm based in San Francisco, California, that specializes in investing in early-stage digital health startups. Founded in 2010, the firm focuses on supporting entrepreneurs who are developing innovative solutions at the intersection of healthcare and technology. It provides funding, access to a network of venture and corporate partners, legal support, and office space to its portfolio companies. Rock Health aims to invest in companies that create health-oriented products, such as activity-tracking devices, telemedicine applications, and data analytics tools that improve healthcare outcomes and reduce costs. Its notable portfolio includes startups like Omada Health, Collective Health, and Doctor on Demand, which are dedicated to enhancing healthcare accessibility and effectiveness. The firm typically considers investments ranging from $0.1 to $0.25 million per company.

Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing therapeutics aimed at addressing significant unmet medical needs in cancer treatment, particularly those related to abnormal gene expression and drug resistance. The company's lead product candidates include CPI-0610, currently undergoing Phase II clinical trials for myelofibrosis in combination with ruxolitinib, and CPI-1205, which is in Phase Ib/II trials for metastatic castration-resistant prostate cancer alongside androgen receptor signaling inhibitors. Additionally, Constellation is developing CPI-0209, which is in the dose escalation phase of a Phase I/II clinical trial for solid tumors. Founded in 2008, the company was previously known as Epigenetix, Inc. and has established itself as a pioneer in the emerging field of epigenetics, which focuses on selective regulators of epigenetic function crucial for gene expression control.

Curis, Inc. is a biotechnology company focused on the discovery and development of innovative drug candidates for the treatment of various human cancers. Based in Lexington, Massachusetts, Curis is advancing several clinical-stage drug candidates, including CA-4948, an oral small molecule currently in Phase I trials for non-Hodgkin lymphomas and acute myeloid leukemia, and Fimepinostat, which targets specific enzymes for MYC-altered diffuse large B-cell lymphoma. The company also has additional pipeline products such as CA-170 for advanced solid tumors and CA-327, which is in the pre-investigational new drug stage. Curis collaborates with notable partners like F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development of Erivedge, a small molecule designed to inhibit the hedgehog signaling pathway in advanced basal cell carcinoma, among other partnerships aimed at enhancing immuno-oncology and precision oncology efforts. Founded in 2000, Curis aims to leverage its expertise in signaling pathways to create targeted cancer therapies.

23andMe, Inc. is a consumer genetics company that provides DNA analysis services through home-based saliva collection kits, enabling users to explore their ancestry, inherited traits, and health insights. Founded in 2006 and headquartered in Sunnyvale, California, the company offers various services, including Health + Ancestry and Ancestry + Traits, which provide insights into a person's genetic background and over 30 trait reports. 23andMe aims to help individuals understand the implications of their genetic information while also catering to researchers by offering categorized and searchable data. The company was co-founded by Linda Avey and Anne Wojcicki and has positioned itself as a significant player in the growing biotechnology and healthcare sectors.

Tanox, Inc. is a a biotechnology company, engages in the discovery and development of therapeutic monoclonal antibodies.

Tolerx, Inc. is a biotechnology company based in Cambridge, Massachusetts, established in 2000. The company specializes in developing novel therapies that modulate T-cell activities for the treatment of autoimmune diseases, diabetes, and cancer. Among its notable products is otelixizumab, a targeted T-cell immunomodulator designed specifically for type 1 diabetes. Additionally, Tolerx is advancing MTRX1011A, an anti-CD4 antibody aimed at various autoimmune conditions, as well as pre-clinical candidates TRX518 and TRX385, which focus on enhancing immune responses for cancer and chronic viral diseases.

HistoRx is developing theranostic solutions to towards individualized patient care. HistoRx's proprietary technology delivers objective and reproducible multiparametric analysis of proteins in tissue, providing insights into cancer treatment.

GlobeImmune, Inc. is a biopharmaceutical company based in Louisville, Colorado, dedicated to developing therapeutic products for cancer and infectious diseases through its proprietary Tarmogen platform. The company’s pipeline includes GS-4774, currently in Phase 2 trials for hepatitis B virus treatment, and various candidates targeting cancer, such as GI-6207 for medullary thyroid cancer, GI-6301 for tumors expressing the brachyury protein, and GI-4000 for resected pancreatic cancer. Additionally, GlobeImmune is advancing several candidates for infectious diseases, including GI-19000 for tuberculosis, GI-2010 for HIV, and GI-18000 for hepatitis D virus, currently in preclinical stages. The Tarmogen platform also includes products designed to address challenges in cancer therapy, such as preventing the emergence of mutated escape variants. The company has established strategic collaborations with Gilead Sciences and Celgene Corporation. Originally founded as Ceres Pharmaceuticals in 1995, GlobeImmune changed its name in 2001 to reflect its focus on innovative immunotherapy solutions.

Kereos, Inc. is a biopharmaceutical company based in Saint Louis, Missouri, specializing in the development of targeted molecular imaging agents and therapeutics aimed at detecting and treating cancer and cardiovascular diseases. Established in 1999, Kereos utilizes a nanoscale drug delivery technology that enhances the targeting and efficacy of various therapeutic compounds, including existing drugs, new candidates, and those that may be too toxic or fragile for conventional delivery methods. The company's product portfolio includes KER-1001, a cancer therapeutic that combines paclitaxel with a targeted nanodroplet, KER-1002, which integrates a natural anti-tumor agent, and KER-1003, known for its anti-angiogenic properties. Additionally, Kereos offers diagnostic solutions such as KER 0001, designed to detect angiogenesis. The company also collaborates with pharmaceutical and imaging firms to further develop its MRI agents and targeted chemotherapeutics for solid tumors and cardiovascular applications.

Tolerx, Inc. is a biotechnology company based in Cambridge, Massachusetts, established in 2000. The company specializes in developing novel therapies that modulate T-cell activities for the treatment of autoimmune diseases, diabetes, and cancer. Among its notable products is otelixizumab, a targeted T-cell immunomodulator designed specifically for type 1 diabetes. Additionally, Tolerx is advancing MTRX1011A, an anti-CD4 antibody aimed at various autoimmune conditions, as well as pre-clinical candidates TRX518 and TRX385, which focus on enhancing immune responses for cancer and chronic viral diseases.

Cellective Therapeutics is a biopharmaceutical company that engages in B Cell research for cancer and autoimmune diseases. Cellective focuses on monoclonal antibodies, which, with the company's technology, can be developed so specifically that they block the root causes of autoimmunity without interfering with the body's normal response to infections.

Cellective Therapeutics was founded with technology created by Dr. Tom Tedder, a recognized world leader in B-cell biology and Chairman of the Department of Immunology at Duke University. Dr. Tedder's team focused on research done in B cells, cells that form an important component of the normal immune system and are hyperactive in people with autoimmune disorders. This hyperactivity of B cells can cause tissue inflammation and organ system dysfunction. With autoimmune diseases like lupus, multiple sclerosis and rheumatoid arthritis, the body actually rejects itself, as if organs were transplanted from someone else. Cellective's research focuses on monoclonal antibodies, which, with the company's technology, can be developed so specifically that they block the root causes of autoimmunity without interfering with the body's normal response to infections.

Tercica Inc., a biotechnology company, engages in the development and commercialization of therapeutics for the treatment of endocrine and metabolic diseases. Its products include Increlex, an rDNA origin injection for the long-term treatment of children with short stature due to severe primary IGFD; and Somatuline Depot, a lanreotide injection for the treatment of adults with acromegaly. Tercica Inc. has strategic partnerships with Genentech and Ipsen SA. The company was founded in 2002 and is based in Brisbane, California. As of October 16, 2008, Tercica Inc. operates as a subsidiary of Ipsen S.A.